Sartorius Stedim Biotech Sets New Growth Targets with Biopharma Focus

On March 17, 2026, Sartorius Stedim Biotech, a key provider of biologics manufacturing technologies, outlined its new strategy focused on biopharma customers at its Capital Markets Day in Aubagne, France. The company aims to expand in high-growth markets by strengthening its portfolio in core bioprocessing technologies and emerging sectors like advanced therapies and process analytics. This strategic shift addresses increasing industry demands for efficiency and reliability, amid a growing biopharmaceutical market.

The global revenues of biologics have surpassed traditional therapies, expected to comprise 57% of global pharma sales by 2030. Sartorius Stedim Biotech plans to outpace market growth by 9-12% annually, focusing on operational efficiency and product innovation to boost profitability. Mid-term goals include enhancing supply chain performance and customer experience.